Semaglutide: FDA Approvals, Clinical Trials & Market Impact

Development & FDA Approval Timeline

Dec 2017

Ozempic Approved

FDA approves once-weekly semaglutide 0.5mg and 1.0mg for type 2 diabetes

Sep 2019

Rybelsus Approved

First oral GLP-1 RA approved for type 2 diabetes

Jun 2021

Wegovy Approved

FDA approves 2.4mg dose for chronic weight management (adults)

Dec 2022

Wegovy Adolescent Approval

FDA expands indication to adolescents 12+ with obesity

Mar 2024

SELECT Trial Results Published

NEJM publishes cardiovascular outcomes data; 20% MACE reduction

Population: 17,604 adults with overweight/obesity and established cardiovascular disease
Duration: Median follow-up of 39.8 months
Primary endpoint: Major adverse cardiovascular events (MACE)
Comparator: Placebo, both arms receiving standard of care

Primary outcome: 20% relative risk reduction in MACE (HR 0.80; 95% CI, 0.72-0.90)
Absolute benefit: 6.5% vs 8.0% event rate over ~3.3 years
NNT: Approximately 67 patients to prevent one MACE event
Weight loss: Mean 9.4% vs 0.9% at 104 weeks
Safety: Gastrointestinal events more common; gallbladder disease increased

Source: Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2024.

Product	Indication	FDA Approved	Maintenance Dose
Ozempic	Type 2 diabetes	2017	0.5-2.0mg weekly
Wegovy	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)	2021	2.4mg weekly
Rybelsus	Type 2 diabetes	2019	7-14mg daily

Semaglutide's success has transformed both the diabetes and obesity treatment landscapes:

Novo Nordisk valuation: Market cap exceeded $400B in 2024, making it Europe's most valuable company
Supply constraints: Chronic shortages led to FDA shortage listings and compounding pharmacy involvement
Competitor response: Eli Lilly's tirzepatide (Mounjaro/Zepbound) approved; other GLP-1/GIP combinations in development
Insurance dynamics: Ongoing debates about coverage for obesity indications; Medicare restrictions under review
Cardiology paradigm shift: SELECT results establish obesity pharmacotherapy as cardiovascular risk reduction strategy

FLOW: Kidney outcomes in T2DM with CKD (estimated completion 2024)
SELECT-OS: Long-term outcomes extension of SELECT population
SOUL: Oral semaglutide cardiovascular outcomes in T2DM
NAVIGATE: Pediatric obesity (ages 6-12)
Alzheimer's studies: Early-phase trials evaluating neuroprotective potential

FDA Warnings (2023-2024):

Risk of ileus added to labeling (September 2023)
Suicidal ideation and hair loss reports under investigation
Thyroid C-cell tumor warnings (boxed warning based on rodent data)
Compounded versions: FDA warning letters issued to facilities violating quality standards

Track prescribed semaglutide with Jabbit's FDA-approved medication features